Promising results of Phase I diabetes trial announced
Promising results of the Phase I clinical trial of the generic drug BCG (bacillus Calmette-Guerin) to treat advanced type I diabetes were announced today at the American Diabetes Association scientific sessions in San Diego. A research team led by Denise Faustman, MD, PhD, director of the Massachusetts General Hospital (MGH) Immunobiology Laboratory is presenting two abstracts (No. 2240-PO and No. 0057-LB) the first which describes the apparent reproduction in human patients of the mechanism that reversed type 1 diabetes in a mouse model and the second proposing that lack of a key part of that mechanism may explain why recent trials of an antibody-based diabetes therapy were not successful. The Iacocca Foundation has been the primary supporter of this work.